United States patent law

HeartBeam Reports First Quarter 2024 Results

Retrieved on: 
Donnerstag, Mai 9, 2024
Cardiology, Software, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, Clinical Trials, FDA, Arrhythmia, Vectorcardiography, VCG, Research, United States patent law, Doctor of Philosophy, ECG, Artificial intelligence, Webcast, 3D, Intelligence, Consultant, Atrial flutter, Patient, Patent, Algorithm, Medical device

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the first quarter ended March 31, 2024.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the first quarter ended March 31, 2024.
  • Research and development expenses for the first quarter of 2024 were $2.4 million, compared to $1.7 million for the first quarter of 2023.
  • General and administrative expenses for the first quarter of 2024 were $2.4 million compared to $2.5 million for the first quarter of 2023.
  • Net loss for the first quarter of 2024 was $4.6 million, compared to a net loss of $4.1 million for the first quarter of 2023.

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

Retrieved on: 
Donnerstag, Mai 9, 2024
CRC, FDA, University, STS, AML, Anthracycline, Virus, Acute myeloid leukemia, United States patent law, Pharmaceutical industry

HOUSTON, May 9, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for U.S. Patent number 11,980,634 titled, "Method of Reconstituting Liposomal Annamycin" (the '634 patent') to be issued on May 14, 2024 to Moleculin and The University of Texas System Board of Regents.

Key Points: 
  • When issued, the patent will provide claims to liposomal Annamycin suspension compositions with a base patent term currently extending until June 2040, subject to extension to account for time required to fulfill regulatory requirements for FDA approval.
  • Moleculin's novel candidate for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets) uses a unique lipid-based delivery technology.
  • In addition to the expected '634 patent and recently issued '118 patent , Moleculin has additional patent applications related to Annamycin pending in the U.S. and in major jurisdictions worldwide.
  • Walter Klemp, CEO and Chairman of Moleculin, stated, "We remain committed to establishing a robust patent estate for Annamycin and driving its development forward.

BioStem Technologies Granted Prioritized Examination for Wound Healing Patent

Retrieved on: 
Montag, Mai 6, 2024
OTC, United States patent law, Patent, Patient, Regenerative medicine, Pharmaceutical industry

POMPANO BEACH, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company’s request for Prioritized Examination for its application for U.S. Patent 18/290,914 titled STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF.

Key Points: 
  • POMPANO BEACH, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company’s request for Prioritized Examination for its application for U.S. Patent 18/290,914 titled STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF.
  • “This patent relates to our proprietary BioREtain® processing, which is at the root of our product technology, what differentiates us from our competitors, and ultimately what helps support wound care treatment for patients.
  • We look forward to working with the USPTO as our application undergoes priority examination.”
    Once granted, the patent will protect BioStem’s method of processing human amniotic tissue.
  • The global wound care dressing market was valued at $14.20 billion in 2023 and is projected to grow at a CAGR of 4.16% from 2024 to 2030.

2024 Gartner® Voice of the Customer Report Named Whatfix a Customers' Choice for Digital Adoption Platforms

Retrieved on: 
Montag, Mai 6, 2024
Knowledge, AXS, Olam, Customer, ROI, BD (company), Integration, ARR, AutoZone, Cisco, Schneider Electric, United States patent law, Beacon Building Products, Avnet, Genuine Parts Company, DAP, Research, Arrow Electronics, Software as a service, NPS, Champions League, Electronics, Microsoft, B2B, Professional, CSAT, Human voice, Communication, IDC, WEEM, Enterprise, SAN, Aramark

SAN JOSE, Calif. and BANGALORE, India, May 6, 2024 /PRNewswire/ -- Whatfix , the global digital adoption platforms (DAP) leader, has been recognized as a Customers' Choice in the Gartner report.

Key Points: 
  • SAN JOSE, Calif. and BANGALORE, India, May 6, 2024 /PRNewswire/ -- Whatfix , the global digital adoption platforms (DAP) leader, has been recognized as a Customers' Choice in the Gartner report.
  • This distinction placed Whatfix in the top-right section of Peer Insights Quadrant, the only DAP vendor that received this recognition.
  • Enterprise bank with $3B+ to $10B in annual revenue said, "Overall, it's been a great experience with Whatfix.
  • You can read the 2024 Gartner® Voice of the Customer for Digital Adoption Platforms report here.

Fullpower®-AI Announces Issuance of Five New Patents, Enhancing Its Leadership in Sleep and Wellness Technologies

Retrieved on: 
Donnerstag, Mai 2, 2024
Meditation, Health, United States patent law, Environment, Science, Patent, Temperature, Sleep, Pet, Data collection, Pharmaceutical industry

These patents underscore Fullpower®-AI's commitment to advancing the science of sleep and wellness through cutting-edge technology.

Key Points: 
  • These patents underscore Fullpower®-AI's commitment to advancing the science of sleep and wellness through cutting-edge technology.
  • US Patent 11,972,775 - This patent introduces an innovative system for collecting sleep data in noisy environments.
  • Issued on April 23, 2024, this patent emphasizes Fullpower®-AI's dedication to improving sleep quality regardless of environmental disturbances.
  • "These patents represent significant technological advancements and reinforce our leadership in the sleep and wellness industries," said Philippe Kahn, CEO of Fullpower®-AI.

Vizgen Issued a New US Patent for Its MERFISH Technology

Retrieved on: 
Dienstag, April 16, 2024
Research, Patent Law, Genetics, Health Technology, Professional Services, Biotechnology, Health, Other Science, Science, United States patent law, RNA, Harvard College, Patent, Chemistry, PTAB, AACR, Harvard University, Inter partes review

Vizgen has secured key patents protecting its innovative pioneering technology in the United States and abroad, adding to its growing patent portfolio as Vizgen continues to invest in the development of its groundbreaking technologies.

Key Points: 
  • Vizgen has secured key patents protecting its innovative pioneering technology in the United States and abroad, adding to its growing patent portfolio as Vizgen continues to invest in the development of its groundbreaking technologies.
  • This newly allowed patent is owned by The President and Fellows of Harvard College and is exclusively licensed to Vizgen.
  • To date, there are over two hundred peer-reviewed and preprint publications on MERFISH technology and thousands of samples have been processed on MERSCOPE instruments.
  • During AACR 2024, Vizgen unveiled the MERSCOPE® Ultra Platform and shared new MERFISH 2.0 chemistry data.

Exactech Strengthens Position as Soft Tissue Balancing Technology Leader with New Patents

Retrieved on: 
Montag, April 22, 2024
Patent, Orientation, Patient satisfaction, Patient, Motion, United States patent law, 3D printing

The two newly granted patents build on a previously awarded patent by broadening the scope of position and orientation of the mechanical actuators in the company's Newton soft tissue balancing device.

Key Points: 
  • The two newly granted patents build on a previously awarded patent by broadening the scope of position and orientation of the mechanical actuators in the company's Newton soft tissue balancing device.
  • "Exactech is committed to leading the industry with innovative soft tissue management technologies that address the growing need for improved patient satisfaction and outcomes in knee replacement," said Laurent Angibaud, Vice President of Advanced Surgical Technologies Development at Exactech.
  • "These newly awarded patents add to Exactech's strong IP portfolio of more than 45 global patents that are dedicated to soft-tissue management, protecting our innovations that offer patients the balanced outcomes they deserve."
  • Powered by Active Intelligence® , the Newton Knee technique works in concert with ExactechGPS® to provide orthopaedic surgeons with dynamic soft tissue analytics, pre-resection operative insights and full-range personalized planning designed to simplify, evaluate and execute balanced total knee replacement surgery.

Privacy4Cars Awarded Three More Patents as New Regulations Require Deletion of Consumer Personal Data Stored in Vehicles in New Jersey and Illinois

Retrieved on: 
Donnerstag, April 18, 2024
Computer vision, IP, Mouth, News, AI, United States patent law, OEM, Software as a service, Artificial intelligence, Patent, Record, Privacy, IDS, Facial recognition, Trust, ALPR, System

ATLANTA, April 18, 2024 /PRNewswire-PRWeb/ -- Privacy4Cars, the first privacy-tech company focused on solving the privacy and security issues posed by vehicle data to protect consumers and automotive businesses, announced today the US Patent Office approved three new patents.

Key Points: 
  • It includes the world's first privacy labeling system covering circa 600 million vehicles across the US, Canada, the UK, and the EU.
  • The third patent is an expansion of the company's signature method to delete personal information stored in vehicles and to create records of deletion.
  • Hundreds of companies already rely on Privacy4Cars' AutoCleared™ data deletion service - and its distinctive IP now includes six patents.
  • Privacy4Cars' newly-awarded patents will fuel the expansion of its product offering, adding to its already robust suite of privacy tools.

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

Retrieved on: 
Donnerstag, April 18, 2024
CRC, STS, Food, United States patent law, Orphan, Research, AML, Anthracycline, European, EMA, Virus, Patent, Diagnosis, Orphan drug, European Medicines Agency, Pharmaceutical industry

HOUSTON, April 18, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of AML.

Key Points: 
  • Recruitment in MB-106 has ended for 2nd line subjects while recruitment for 1st line and 3rd line subjects continue.
  • The EMA grants orphan drug designation to drugs and biologics intended for the treatment, diagnosis or prevention of rare, life-threatening or chronically debilitating diseases or conditions that affect fewer than five in 10,000 people in the European Union.
  • Orphan designation allows companies certain benefits, including reduced regulatory fees, clinical protocol assistance, research grants and up to 10 years of potential market exclusivity in the European Union if approved.
  • Annamycin currently has Fast Track Status and Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of relapsed or refractory AML, in addition to Orphan Drug Designation for the treatment of STS lung mets.

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

Retrieved on: 
Mittwoch, April 10, 2024
Cardiotoxicity, RTCA, Mouse, STS, Doxorubicin, Heart, Animal, Molecule, Pathology, AML, Potent, Anthracycline, DNA, Patent, Patient, Physiology, Virus, Toxicity, Acute myeloid leukemia, AACR, United States patent law, Pharmaceutical industry

HOUSTON, April 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced positive preclinical data regarding the Company's next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego, CA.

Key Points: 
  • The poster titled, Non-cardiotoxic Properties of Annamycin, a Clinically Evaluated Anthracycline and Potent Topoisomerase 2β Poison , was presented in the "Late-Breaking Research: Experimental and Molecular Therapeutics 2" session held on Monday, April 8th.
  • These data, documenting lack of cardiotoxicity of Annamycin and aligned with the data demonstrated to date in our ongoing clinical trials, bolster our confidence in Annamycin potential to offer patients a safe and effective treatment option.
  • Annamycin and doxorubicin cytotoxicity was assessed in a panel of cancer cell lines cardiomyocytes (murine and human).
  • For more information about the ongoing trials, please visit clinicaltrialsregister.eu : EudraCT 2020-005493-10 or clinicaltrials.gov : NCT05319587; and clinicaltrials.gov : NCT04887298, respectively.